Phage therapy shown to kill drug-resistant superbug
13 December 2019
Scientists from the University of Liverpool‘s Institute of Infection and Global Health have shown that phage therapy could offer a safe and effective alternative to antibitotics in the treatment of cystic fibrosis lung infections.
Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio).
Further reading: Stock Daily Dish
Author(s): Stock Daily Dish
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
